Shanghai Kaibao Pharmaceutical (300039) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Shanghai Kaibao Pharmaceutical ¥4.25, price ¥5.30, upside -19.8%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Kaibao Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥3.66 – ¥11.95 · fair‑value band ¥3.19 – ¥5.51 · the ¥5.30 price screens above the ¥4.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Shanghai Kaibao Pharmaceutical in your weekly email
Every Wednesday you see whether Shanghai Kaibao Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China.
Show more
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai'an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. The company was founded in 2000 and is based in Shanghai, China.
Stock analysis
Shanghai Kaibao Pharmaceutical (300039) currently trades at ¥5.30, while our model-based Fair Value estimate is ¥4.25, implying the stock looks roughly 24.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥4.59 per share, and 3 of the 24 models we run sit above the ¥5.30 price.
Bear case: the Dividend Discount group reads lowest at ¥1.60, and 21 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥3.19 (bear) to ¥5.51 (bull), the price of ¥5.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Shanghai Kaibao Pharmaceutical reported revenue of 1.2B CNY in FY2025 versus 1.1B CNY in FY2021, a compound +1.2%/yr. Reported net income was 279M CNY in FY2025, compounding +18.7%/yr from FY2021.
Key figures
Market cap 5.5B CNY (≈ $828M) · P/E ratio 21.2 · P/S ratio 5.12 · EPS (TTM) ¥0.2500 · Dividend yield 2.5% · Net margin 24.2% · Return on equity 5.8% · Return on assets (EBIT) 6.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −20%, 300039 screens richer than that median.
Fair Value models
Bear ¥3.19Fair Value ¥4.25Bull ¥5.51
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0878 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−21.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Start year 2020 (pandemic). Over 10 years: −1.9% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.7%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.15% vs 0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 24%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +12.4% a year for the price.
Compare Shanghai Kaibao Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−20% · Below median
Profitability
Return on equity (TTM)6% · Below median
Return on assets3% · Above median
Net margin (TTM)25% · Top 25%
Operating margin (TTM)24% · Top 25%
Growth and dividend
Revenue growth−29% · Bottom 25%
Dividend yield (TTM)2.5% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shanghai Kaibao Pharmaceutical (300039) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥4.25 versus a price of ¥5.30, about −20% upside (overvalued).
What is the fair value of 300039?
Our model-based fair value for Shanghai Kaibao Pharmaceutical is ¥4.25 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥5.30.
What is the quality score of 300039?
Shanghai Kaibao Pharmaceutical has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Kaibao Pharmaceutical (300039)?
Our model-based price target is the fair value of ¥4.25 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario ¥3.19, optimistic scenario ¥5.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Kaibao Pharmaceutical stock forecast for 2026?
Our models put fair value at ¥4.25, about −20% upside versus a price of ¥5.30 (overvalued). Cautious scenario ¥3.19, optimistic scenario ¥5.51. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Kaibao Pharmaceutical (300039)?
Shanghai Kaibao Pharmaceutical reported trailing-twelve-month revenue of about 1.0B CNY (latest available figure, as of Sep 23, 2026).
Does Shanghai Kaibao Pharmaceutical pay a dividend?
Shanghai Kaibao Pharmaceutical currently shows a dividend yield of about 2.45% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Shanghai Kaibao Pharmaceutical (300039)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Kaibao Pharmaceutical would have to grow free cash flow by +14.3 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.9 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 300039 use?
Our models discount Shanghai Kaibao Pharmaceutical at 10.4 %: a base by market capitalisation (small), damped by beta 0.24, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Kaibao Pharmaceutical that is +14.3 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shanghai Kaibao Pharmaceutical (300039) delivered so far?
Over the past 5 years revenue at Shanghai Kaibao Pharmaceutical grew +4.9 % a year. The price currently implies +14.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Kaibao Pharmaceutical (300039) growing?
The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into Shanghai Kaibao Pharmaceutical (+14.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Kaibao Pharmaceutical (300039)?
The free-cash-flow yield on the price is 3.67 %: that much free cash flow Shanghai Kaibao Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Kaibao Pharmaceutical (300039)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Kaibao Pharmaceutical it is ¥4.25 per share (as of Sep 23, 2026), against a price of ¥5.30. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Kaibao Pharmaceutical stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 300039 trades above its calculated fair value: price ¥5.30, fair value ¥4.25, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300039?
No. The price is what the market pays today (¥5.30); the fair value is what the company's own numbers justify (¥4.25). For Shanghai Kaibao Pharmaceutical the two are ¥1.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Kaibao Pharmaceutical worth?
The market values Shanghai Kaibao Pharmaceutical at about 5.5B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥5.30; our models calculate a fair value of ¥4.25 per share.
What do the bullish and bearish scenarios say about 300039?
Our models span a range for Shanghai Kaibao Pharmaceutical: cautious scenario ¥3.19, base ¥4.25, optimistic ¥5.51 per share (as of Sep 23, 2026, price ¥5.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300039?
Shanghai Kaibao Pharmaceutical trades at a price-to-earnings ratio of 21.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.25 is built from several models across several years. Other multiples: P/B 1.3, P/S 5.4, EV/EBITDA 16.8.
How solid is the balance sheet of Shanghai Kaibao Pharmaceutical (300039)?
Balance-sheet figures for Shanghai Kaibao Pharmaceutical (as of Sep 23, 2026): return on equity 5.8%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 300039 from its 52-week high?
Shanghai Kaibao Pharmaceutical trades at ¥5.30, about 19% below its 52-week high of ¥6.54 and 27% above the low of ¥4.18 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.25 is for.
Which stocks are comparable to Shanghai Kaibao Pharmaceutical?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Kaibao Pharmaceutical stock attractive at the current price?
The data as of Sep 23, 2026: price ¥5.30, calculated fair value ¥4.25 (−20%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300039 calculated?
We run Shanghai Kaibao Pharmaceutical through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Shanghai Kaibao Pharmaceutical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Kaibao Pharmaceutical (300039)?
The closing price on Sep 22, 2026 was ¥5.30. Our model-based fair value is ¥4.25, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Kaibao Pharmaceutical right now?
Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Shanghai Kaibao Pharmaceutical (300039) come from?
Earnings per share at Shanghai Kaibao Pharmaceutical grew −0.4 % a year from 2013 to 2024. Broken into its drivers: revenue per share −0.1 %, EBIT margin +0.0 %, tax rate +0.1 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shanghai Kaibao Pharmaceutical
How large is the market capitalisation of Shanghai Kaibao Pharmaceutical (300039)?
The market capitalisation of Shanghai Kaibao Pharmaceutical is 5.5B CNY (≈ $828M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Kaibao Pharmaceutical (300039)?
The price-to-sales ratio of Shanghai Kaibao Pharmaceutical is 5.12 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Kaibao Pharmaceutical (300039)?
Earnings per share at Shanghai Kaibao Pharmaceutical are ¥0.2500 (price ÷ EPS = P/E 21.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Kaibao Pharmaceutical (300039)?
The dividend yield of Shanghai Kaibao Pharmaceutical is 2.5% (payout 52.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Kaibao Pharmaceutical (300039)?
The net margin of Shanghai Kaibao Pharmaceutical is 24.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Kaibao Pharmaceutical (300039)?
The return on equity (ROE) of Shanghai Kaibao Pharmaceutical is 5.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Kaibao Pharmaceutical (300039)?
On an EBIT basis the return on assets of Shanghai Kaibao Pharmaceutical is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Kaibao Pharmaceutical (300039)?
The operating margin of Shanghai Kaibao Pharmaceutical is 24.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Kaibao Pharmaceutical (300039)?
Revenue at Shanghai Kaibao Pharmaceutical is growing −29.3% versus a year earlier (3y avg +1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Kaibao Pharmaceutical (300039)?
Earnings per share at Shanghai Kaibao Pharmaceutical are growing −23.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai Kaibao Pharmaceutical (300039) hold?
Shanghai Kaibao Pharmaceutical holds more cash than debt, 588M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Kaibao Pharmaceutical in the live analysis
One click puts Shanghai Kaibao Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
